News

Media Centre

Cristal Therapeutics Awarded Horizon 2020 Grant to Further Develop the CriPec® Nanomedicine Platform 2 July 2020
Cristal Therapeutics Publishes Positive Data on its CriPec® Nanomedicine Technology in Small 11 May 2020
Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer 1 August 2019
Cristal Therapeutics to present data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on lead clinical candidate CPC634 in patients with solid tumors 17 May 2019
Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline 1 November 2018
Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer 24 October 2018
Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials 28 November 2017
Cristal Therapeutics progresses nanomedicine CriPec®-docetaxel to phase 1b development in patients with solid tumours 1 November 2017
Dr. Istvan Udvaros joins Cristal Therapeutics as New Chief Medical Officer 24 October 2017
Cristal Therapeutics further strengthens its Scientific Advisory Board with appointment of Dr. Paul Lammers 9 August 2017
Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec® nanotech platform 19 January 2017
Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal’s CriPec® nanotech platform 6 December 2016
Cristal Therapeutics announces appointment of Edwin Klumper as Chief Medical Officer 29 April 2016
Cristal Therapeutics starts clinical phase I trial with nanomedicine CriPec® docetaxel in patients with solid tumours 29 September 2015
Cristal Therapeutics Announces Collaboration With PX Biosolutions to Develop CriVac® Based vaccines 14 July 2015
Cristal Therapeutics’ proprietary CriPec® nanomedicine platform and promising preclinical data highlighted in three recent publications 22 June 2015
Cristal Therapeutics announces formation of Scientific Advisory Board 22 May 2015
Cristal Therapeutics announces appointment of Jeroen Tonnaer as Chief Business Officer 21 April 2015
€6 million in new capital and new CEO 16 December 2014
Cristal Therapeutics and Enabling Technologies 24 March 2014
Cristal Therapeutics raises additional funding for its lead product CriPec® docetaxel 1 July 2013
Nedermaas Ventures en Innovatiefonds investeren in Cristal Delivery 29 May 2013
Cristal Delivery wint Utrechtse Ster 2012 31 October 2012
Nanomedicijn bedrijf Cristal Delivery verhoogt de therapeutische waarde van geneesmiddelen 14 June 2011